title: The Story of Antenatal Steroid Therapy before Preterm Birth.
abstract: Antenatal glucocorticoid has proven to be one of the most successful single therapeutic approaches for preventing serious consequences after preterm birth. The fetal compartment is protected against endogenous corticosteroid by the high endogenous 11β-hydroxysteroid dehydrogenase type 2 that converts cortisol to cortisone and by the poor responsiveness of the fetal hypothalamus to corticotropin-releasing hormone. High corticosteroid activity acutely enhances the functional maturity of the fetus. Persistently high fetal glucocorticoid activity has adverse effects on the growth and differentiation of the fetal brain and other organs. Intrauterine growth restriction may be associated with high fetal glucocorticoid activity. Antenatal glucocorticoid therapy which is aimed to be given within 1-10 days before preterm birth is likely to increase the success of postnatal noninvasive treatments of very preterm infants.
authors.affiliation: PEDEGO Research Center and Medical Research Center Oulu, University of Oulu, and Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland.
authors.forename: Mikko
authors.initials: M
authors.lastname: Hallman
mesh_terms: D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000188:drug therapy*; D005333:Fetus / Q000187:drug effects*; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007226:Infant Mortality; D062071:Infant, Extremely Premature / Q000254:growth & development*; D007231:Infant, Newborn; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D047928:Premature Birth; D016032:Randomized Controlled Trials as Topic
chemical_list: D005938:Glucocorticoids